Untitled

Calvo, Pilar; Sánchez, Alejandro; Martínez, Jesús María Bachiller; López, María Isabel; Calonge, Margarita; Pastor, J. Carlos; Alonso, Marı́a José

doi:10.1023/a:1016015803611

Cited by 101 publications

(20 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Calvo et al [100] have prepared nanocapsules composed of an oily phase loaded with CsA (Mygliol) surrounded by a poly- ε -caprolactone (PCL) coat. After topical administration, these nanocapsules were taken up by corneal epithelial cells and achieved corneal levels of CsA that were five times higher than a 10 mg/mL CsA oily solution.…”

Section: Treatment Of Dry Eye Syndrome (Des)mentioning

confidence: 99%

An Overview on Dry Eye Treatment: Approaches for Cyclosporin A Delivery

Yavuz

Pehlivan

Ünlü

2012

The Scientific World Journal

View full text Add to dashboard Cite

Dry eye syndrome (DES, Keratoconjunctivitis sicca) is a common disorder of the tear film caused by decreased tear production or increased evaporation. Changes in tear composition also promote inflammation on the ocular surface by various mechanisms. Artificial tear drops, tear retention treatment, stimulation of tear secretion, or anti-inflammatory drugs may be used for dry eye treatment according to the severity of the disease. For untreated patients, the risk of ocular infection increases at considerable level and clinical course of the disease may proceed up to infection, corneal ulcer, and blindness. Artificial tears and/or punctual occlusions are used for tear replacement or preservation. New treatment approaches are designed to modify the underlying disease process. For the treatment of severe dry eye disease, cyclosporin A (CsA), the first one of the new generation immunomodulatory drugs, which has an anti-inflammatory effect, is frequently used. CsA has immunosuppressive effects following systemic application. Following local administration of CsA, it is expected to obtain effective drug concentration at the target area and to avoid the various side effects associated with systemic delivery. Microspheres, implants, and liposomes have been developed for administration of CsA subconjunctivally in order to enhance its efficiency.

show abstract

Section: Treatment Of Dry Eye Syndrome (Des)mentioning

confidence: 99%

An Overview on Dry Eye Treatment: Approaches for Cyclosporin A Delivery

Yavuz

Pehlivan

Ünlü

2012

The Scientific World Journal

View full text Add to dashboard Cite

show abstract

“…For example, beta-blockers such as timolol that treat wide-angle glaucoma have a deleterious effect on the heart [5]. In view of the limitations of ocular drug delivery by eye drops, a significant amount of research has been conducted at developing more effective ophthalmic drug delivery systems based on polymeric gels such as hyaluronic acid (HA) [6], poly(acrylic acid) (PAA) [7,8], cellulose [9], soaked collagen shields [2], biodegradable and non-erodible implants [2], and colloidal particles such as liposomes [10,11], nanocapsules [12][13][14][15], contact lenses [16,17], and microemulsions.…”

Section: Introductionmentioning

confidence: 99%

Timolol transport from microemulsions trapped in HEMA gels

Abrahamson

Kapoor

et al. 2007

Journal of Colloid and Interface Science

View full text Add to dashboard Cite

“…[41] [ 3 H-Cyclosporin A (2)-PCL] Topical Albino rabbit PK: Significantly increased corneal AUC (4.3-fold, vs. oily drug solution). [42] ( …”

Section: Ementioning

confidence: 99%

Ocular Disposition, Pharmacokinetics, Efficacy and Safety of Nanoparticle-Formulated Ophthalmic Drugs

Bu¹,

Gukasyan²,

Goulet³

et al. 2007

CDM

View full text Add to dashboard Cite

Ophthalmic drugs are delivered to ocular tissues predominantly via relatively simple formulations, such as topically dosed water-soluble drug solutions and water-insoluble drug suspensions in ointments. An ideal topical drug delivery system should possess certain desirable properties, such as good corneal and conjunctival penetration, prolonged precorneal residence time, easy instillation, non-irritative and comfortable to minimize lachrymation and reflex blinking, and appropriate rheological properties. In general, ocular efficacy is closely related to ocular drug bioavailability, which may be enhanced by increasing corneal drug penetration and prolonging precorneal drug residence time. To improve ocular bioavailability of topically dosed ophthalmic drugs, a variety of ocular drug delivery systems, such as hydrogels, microparticles, nanoparticles, microemulsions, liposomes and collagen shields, have been designed and investigated. These newer systems may, to some extent, control drug release and maintain therapeutic levels in ocular tissues over a prolonged period of time. This review focuses on the in vitro, ex vivo and in vivo studies of ophthalmic drugs formulated in nanoparticles published over the past two decades. The progress and development issues relating to ocular disposition, pharmacokinetics, efficacy and safety of the nanoparticle-formulated ophthalmic drugs are specifically addressed. Information and discussions summarized in this review are helpful for pharmaceutical scientists to develop better ophthalmic therapeutics.

show abstract

Untitled

Abstract: The CyA-loaded nanocapsules are shown to be interesting vehicles for the improvement of the ocular penetration of CyA.

Cited by 101 publications

References 8 publications

An Overview on Dry Eye Treatment: Approaches for Cyclosporin A Delivery

An Overview on Dry Eye Treatment: Approaches for Cyclosporin A Delivery

Timolol transport from microemulsions trapped in HEMA gels

Ocular Disposition, Pharmacokinetics, Efficacy and Safety of Nanoparticle-Formulated Ophthalmic Drugs

Contact Info

Product

Resources

About